NEW YORK, May 30, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced that Company management will make two presentations at the 2nd Baltic Stem Cell Meeting, running from Friday, May 31 to Sunday, June 2, 2013, and that the conference will feature a session with multiple researchers from around the world discussing advances using very small embryonic-like stem cells (VSELs™ Technology).
The conference focuses on innovative applications of stem cells in multiple areas, the clinical application of umbilical cord blood in regenerative medicine, news and updates on VSEL™ Technology, stem cell mobilization and homing, novel directions in hematopoietic transplants, stem cells and cancer, stem cells and aging, and more. Dr. Robin L. Smith, Chairman and CEO of NeoStem, will chair a panel and give a talk titled "From the bench to the clinic: Considerations in cell therapy development." Dr. Denis O. Rodgerson, Director of Stem Cell Science of NeoStem, will speak on "Generation of skeletal structures by human very small embryonic-like (VSEL) stem cells."
The conference will also feature some of the researchers from the United States, Europe and Asia who have expanded on the initial studies of VSEL™ Technology carried out by Dr. Mariusz Ratajczak, including:
- Dr. Diane Krause of Yale University will speak on her recent research on the differentiation of VSELs from murine bone marrow into lung epithelial cells. This research will be published in Stem Cells, May 2013 issue.
- Dr. Magdalena Kucia of the University of Louisville will speak on "Aging – when VSELs meet IGF-1."
- Dr. Yu-Zhu Tan will speak on "Repairing the infarcted myocardium by transplantation of very small embryonic-like stem cells."
- Dr. Marcin Moniuszko will speak on "Effects of vascular dysfunction on circulating endothelial progenitor cells and VSEL stem cells in type 1 diabetes."
- Dr. Deepa Bhartiya of the National Institute for Research in Reproductive Health, Mumbai, India will present on "VSELs in adult mammalian gonads."
- Dr. Dong-Myung Shin of the University of Louisville will present on "Molecular signature of murine and human Oct4+ very small embryonic-like stem cells (VSELs)."
"The research being presented by these scientists both enhances our understanding of the potential of VSELs as the ultimate cell for regenerative therapy and provides further validation of the capabilities of these cells," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "We are happy to see research into VSEL™ Technology by a growing number of scientists who are not affiliated with NeoStem and we welcome the interest of the scientific community in these extraordinary cells."
NeoStem is pursuing a development program relating to its VSEL™ Technology in selected clinical applications and markets based on unmet medical need, target patient population size, regulatory strategy, and overall commercial market. Through both grant funding and NeoStem's own funding, the Company is exploring the potential of VSEL™ Technology in the treatment of periodontitis, healing complex skin and soft tissue wounds, corneal regeneration and repair, age-related macular degeneration, nerve regeneration and acute radiation syndrome in a parallel but staggered timeline. NeoStem anticipates that a single clinical manufacturing process will be developed for these indications, collectively, and that the major pacing item will be the generation of preclinical data to support the filing of an investigational new drug application (IND) for a Phase 1 clinical trial, the first of which it expects to be in periodontitis.
The event takes place at the Radisson SAS Hotel, Szczecin, Poland and is organized by Pomeranian Medical University.
About NeoStem, Inc.
NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
About VSEL™ Technology
Mariusz Ratajczak, M.D., Ph.D., head of the Stem Cell Biology Program at the James Graham Brown Cancer Center at the University of Louisville, discovered that mammalian bone marrow contains a heterogeneous population of stem cells that has properties similar to those of embryonic stem cells. These cells, first described in mice, are referred to as very small embryonic-like (VSEL) stem cells, and the technology is referred to as VSEL™ Technology. NeoStem is engaged in research and development of new therapies based on VSEL™ Technology and pursuant to its license agreement with the University of Louisville, NeoStem has the exclusive, world-wide rights, to technology and know-how relating to very small embryonic-like stem cells. These patent applications, filed in the U.S. and abroad, relate to VSEL™ stem cell methods of isolation and treatment of disease.
The use of human VSELs™ for regenerative medicine presents the possibility of capturing the key advantages associated with embryonic stem cells without the ethical or moral dilemmas associated with the use of fetal cells, or the potential negative biological effects associated with embryonic stem cells, such as their propensity to form tumors. In addition, VSELs™ offer the advantage of using autologous stem cells (i.e., the patient's own cells) for therapy, as opposed to having to rely on donor cells that are susceptible to immune rejection. NeoStem's research has identified cells in human blood and bone marrow that have many of the key properties described for murine VSELs™ . This research includes evidence of primitivism, pluripotency and tri-lineage differentiation. These observations provide the groundwork for the development of VSEL™ therapies to regenerate or repair damaged or diseased tissues in human subjects.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts for cellular therapies, including with respect to AMR-001 and VSEL™ Technology, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: NeoStem Dr. Robin L. Smith Chairman and CEO Phone: +1-212-584-4174 Email: email@example.com